Información del artículo
Se revisa la hiperglucemia pospandrial como factor de riesgo cardiovascular. Se han encontrado suficientes datos fisiopatológicos y de asociación, lo que ha permitido a los estudios de intervención catalogarla con un nivel de evidencia IIb, con un grado de recomendación B. Se recomienda su determinación a las 2 h postingesta y con la frecuencia de la que se deriven modificaciones terapéuticas. Se hace una revisión de diversos fármacos útiles, para lo que se propone un esquema general terapéutico.
Palabras clave:
Hiperglucemia postprandial
Factor de riesgo macrovascular
Tratamiento
Postprandial hyperglycemia as a cardiovascular risk factor is reviewed. Sufficient physiological and associated data were found to allow intervention studies to classify it with level IIb evidence and grade B recommendation. Determinations should be performed 2 hours after food intake and when therapy is modified. Several useful drugs are reviewed and a general therapeutic protocol is proposed.
Key words:
Postprandial hyperglycemia
Macrovascular risk factor
Treatment
El Texto completo está disponible en PDF
Bibliografía
[1.]
B. Tamayo, E. Faure, M.J. Roche, E. Rubio, E. Sánchez, J.A. Salvador.
Prevalence of diabetes and impaired glucose tolerance in Aragón, Spain.
Diabetes Care, 20 (1977), pp. 534-536
[2.]
S.M. Haffner, S. Lehto, T. Ronnemaa, K Pyorala, M. Laakso.
Mortality fron coronary heart disease in subjects with type 2 diabets and in nondiabetic subjects with and without prior myocardial infarction.
New Engl J Med, 339 (1998), pp. 229-234
[3.]
C. Do Lee, A.R. Folsom, J.S. Pankow, F.L. Brancati, For the atherosclerosis risk in communities (ARIC) study investigators.
Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction.
Circulation, 109 (2004), pp. 855-860
[4.]
S.C. Grundy, R. Pasternak, P. Greenland, J. Smith, V. Fuster.
Assessment of cardiovascular risk by use of multiple risk factor assessment equations.
Circulation, 100 (1999), pp. 1481-1482
[5.]
D.A. Greene, S.A. Lattimer, A.A.F. Sima.
Sorbitol, phosphoinositides, and sodium-potassium ATPase in the pathogenesis of diabetic complications.
N Engl J Med, 316 (1987), pp. 599-606
[6.]
P. Xia, T. Inoguchi, T.S. Kern, R.L. Engerman, P.J. Oates, G.L. King.
Characterization of the mechanism for the chronic activation of diacyglycerol-proteinkinase C pathway in diabetes and hypergalactosemia.
Diabetes, 43 (1994), pp. 1122-1129
[7.]
A. Ceriello.
Perspectives in diabetes. Postprandial hyperglycemia and diabetes complications. Is it time to treat?.
Diabetes, 54 (2005), pp. 1-7
[8.]
V. Kolm-Litly, U. Sauer, A. Nerlich, R. Lehmann, E.D. Scheleicher.
High glucose-induced transforming growth factor beta 1 production is mediated by hexosamina pathway in porcine glomerular mesangial cells.
J Clin Invest, 101 (1998), pp. 160-169
[9.]
R. Marfella, K. Esposito, R. Giunta, G. Coppola, L. De Angelis, B. Farzati, et al.
Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia.
Circulation, 101 (2000), pp. 2247-2251
[10.]
K. Esposito, F. Nappo, R. Marfella, G. Giugliano, F. Giugliano, M. Ciotola, et al.
Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans role of oxidative stress.
Circulation, 106 (2002), pp. 2067-2072
[11.]
T. Nishikawa, D. Edelstein, X.L. Du, S. Yamagishi, T. Matsumura, Y. Kaneda, et al.
Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage.
Nature, 13 (2000), pp. 787-790
[12.]
The DECODE Study Group; European Diabetes Epidemiology Group.
Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria.
Lancet, 354 (1999), pp. 617-621
[13.]
M. Coutinho, H.C. Gerstein, Y. Wang, S. Yusuf.
The relationship between glucose and incident cardiovascular events a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years.
Diabetes Care, 22 (1999), pp. 233-240
[14.]
T.S. Temelkova-Kurktschiev, C. Koehler, F. Schaper, W. Leonhardt, H. Henkel, M. Hanefeld.
Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose and HbA1c level.
Diabetes Care, 23 (2000), pp. 1830-1834
[15.]
J.L. Chiasson, R.G. Josee, R. Gomis, M. Hanefeld, A. Karasik, M. Laakso, The STOP-NIDDM Trial Research Group.
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance.
JAMA, 290 (2003), pp. 486-494
[16.]
M. Hanefeld, M. Cagatay, T. Petrowitsch, D. Neuser, D. Petzinna, M. Rupp.
Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of sseven long-term studies.
Eur Heart J, 25 (2004), pp. 10-16
[17.]
K. Malmberg, L. Ryden, H. Wedel, K. Birkeland, A. Bootsma, K. Dickstein, et al.
Fasttrack intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity.
Eur Heart J, 26 (2005), pp. 650-661
[18.]
K. Esposito, D. Giugliano, F. Nappo, R. Marfella, The Campanian postprandial hyperglycemia study group.
Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.
Circulation, 110 (2004), pp. 214-219
[19.]
T.M.S. Wolever, J.L. Chiasson, A. Csima, J.A. Hunt, C. Palmason, S.A. Ross, et al.
Variation of postprandial plasma glucose, palatability, and symptoms associated with a standardized mixed test meal versus 75 g oral glucose.
Diabetes Care, 21 (1998), pp. 336-340
[20.]
American Diabetes Association.
Postprandial blood glucose.
Diabetes Care, 24 (2001), pp. 775-778
[21.]
E. Faure, L.F. Pallardo, J. Mesa, M. Puig-Domingo, R. García-Mayor, P. Benito, et al.
HbA1c and glycemic profile, basal and post-treatment with miglitol, in an area with a Mediterranean diet.
Diabetes Care, 25 (2002), pp. 1896-1897
[22.]
E. Faure.
Nuevos tratamientos en la diabetes mellitus.
Endocr Nutr, 48 (2001), pp. 174-176
[23.]
O.G. Kolterman, J.B. Buse, M.S. Fineman, E. Gaines, S. Heintz, T.A. Bicsak, et al.
Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.
J Clin Endocrinol Metab, 88 (2003), pp. 3082-3089
[24.]
R.A. De Fronzo, R.E. Ratner, J. Han, D.D. Kim, M.S. Finemna, A.D. Baron.
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
Diabetes Care, 28 (2005), pp. 1092-1100
[25.]
D.M. Kendall, M.C. Riddle, J. Rosenstock, D. Zhuang, D.D. Kim, M.S. Fineman, et al.
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.
Diabetes Care, 28 (2005), pp. 1083-1091
[26.]
J.H. Anderson, R.L. Brunelle, V.A. Koivisto, A. Pfützner, M.E. Trautmann, L. Vignati, et al.
Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment.
Diabetes, 46 (1997), pp. 265-270
[27.]
P.A. Holander, L. Blonde, R. Rowe, A.E. Mehta, J.L. Milburn, K.S. Hershon, et al.
Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes.
Diabetes Care, 27 (2004), pp. 2356-2362
[28.]
T. Quattrin, A. Belanger, N.H.J.V. Bohannon, S.L. Schwartz, The exubera phase III study group.
Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes.
Diabetes Care, 27 (2004), pp. 2622-2627
Copyright © 2006. Sociedad Española de Endocrinología y Nutrición
